Amgen Inc.

Healthcare · Drug Manufacturers - General

Overall research band Mixed

Quality Above average

Valuation Above average

Balance sheet Very weak

Market confirmation Above average

One-minute company read

What this report can tell you now

What the company does

Amgen Inc., founded in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology company focused on discovering, developing, manufacturing, and delivering human medicines. The company operates in therapeutic areas such as inflammatory conditions, oncology, hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Amgen's product portfolio includes notable pharmaceuticals like Enbrel, Neulasta, Prolia, Xgeva, Otezla, Aranesp, KYPROLIS, Repatha, Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITA, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company serves healthcare providers such as physicians, clinics, dialysis centers, hospitals, and pharmacies, distributing its therapies worldwide primarily through pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen also engages in strategic collaborations and research partnerships with organizations including Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Eli Lilly and Company, Datos Health, Verastem, Kyowa Kirin, Neumora Therapeutics, and Plexium.

The current research profile is Mixed Setup, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC17.0%Model input; read with the evidence status and period context.

Operating margin29.1%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years9.1%Model input; read with the evidence status and period context.

FCF margin22.0%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.